Considering that HIF-1α activity was correlated with the previously observed benefit of mCHT in the EMT6/CDDP pre-clinical metastatic breast cancer model [16], these findings together validate previous in vitro results and indicate that mCHT can induce HIF-1 α levels even in non-hypoxic cancer cell lines, a phenomenon which can be correlated with cancer stem cell enrichment leading to therapy resistance, tumor recurrence and metastases [17]. The gene discussed is SETD2; the disease is cancer.